Figure 6.

PEG-lipid properties impact internal structure and cellular knockdown efficacy of ASO-LNPs. (A) The 54 formulations are presented using color-coded heat maps to rank-order them based on the relative mRNA expression (left panel) and disordered/H_II peak area ratios (right panel). Two unstable formulations without the primary H_II peaks were excluded from the SAXS model fitting and are indicated in white in the SAXS ratio heat map. (B, C) Correlations among disordered/H_II peak area ratio, PEG-lipid carbon tail length, PEG-lipid molar ratio, and relative mRNA expression across the screening library. **p < 0.05, ***p < 0.001, ****p < 0.0001, NS: nonsignificant, as analyzed by two-tailed t tests. All cellular efficacy and DLS data were obtained from our previous study.¹⁷